RxDoctor Payments Data

Mark Reiter, MD

Internal Medicine · Oak Lawn, ILNPI 1902864408

Payments from drug & device makers

$1,521in general payments, 2019–2025

Across 69 payments — averaging $22.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$239
  • Otsuka America Pharmaceutical, Inc.$176
  • Jazz Pharmaceuticals Inc.$161
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$142
  • Pfizer$112
  • Eisai Inc.$110
  • plus $581 from 12 others

What the payments were for

  • Food & beverage$1,42694%
  • Education$956%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,521 in reported general payments places this provider in the 80th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$21,673
Medicare patients
84
Services billed
241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide21$32,305
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$26,478
RybelsusSemaglutide11$23,088
EliquisApixaban31$22,878
JanuviaSitagliptin Phosphate22$19,882
MounjaroTirzepatide18$19,419
RexultiBrexpiprazole12$17,826
JardianceEmpagliflozin18$17,477
TrulicityDulaglutide11$17,157
EntrestoSacubitril/Valsartan12$13,697
LinzessLinaclotide14$11,331
Breo ElliptaFluticasone/Vilanterol15$9,419
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen136$8,292
MyrbetriqMirabegron14$6,956
XareltoRivaroxaban11$6,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$79$55,39332 claims
Lilly USA, LLCMounjaro, Trulicity$239$36,57529 claims
GSKTrelegy Ellipta, Breo Ellipta$28$35,89741 claims
PfizerEliquis$112$22,87831 claims
MerckJanuvia$58$19,88222 claims
Otsuka America Pharmaceutical, Inc.Rexulti$176$17,82612 claims
Boehringer IngelheimJardiance$32$17,47718 claims
AbbVieLinzess, Synthroid$70$12,47026 claims
Astellas Pharma US IncMyrbetriq$110$6,95614 claims
Johnson & JohnsonXarelto$86$6,27411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Oak Lawn

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →